Skip to main content
Clinical Trials/NCT01114100
NCT01114100
Completed
Phase 4

The Effects of Treatment With Sertraline for Panic Disorder and/or Depression Driven Chest Pain and/or Palpitations in a Double Blind, Care as Usual and Placebo Controlled Study

Maastricht University Medical Center1 site in 1 country210 target enrollmentJanuary 2000

Overview

Phase
Phase 4
Intervention
sertraline
Conditions
Panic Attacks
Sponsor
Maastricht University Medical Center
Enrollment
210
Locations
1
Primary Endpoint
panic attacks
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

The purpose of this study is to determine whether care as usual or intervention (consisting of sertraline versus placebo), are effective in the treatment of panic disorder and/or depression driven noncardiac chest pain.

Detailed Description

Noncardiac chest pain remains an important problem in clinical cardiology. Often, panic disorder and/or depression are the underlying cause. However, this is largely underdiagnosed. There are no clear existing treatment strategies/methods for this specific patient population. In our double blind, placebo controlled care as usual versus sertraline study, we want to investigate whether intervention is more effective as care as usual for diminishing chest pain, and also if sertraline is more effective in this specific population compared to placebo.

Registry
clinicaltrials.gov
Start Date
January 2000
End Date
December 2002
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • chest pain without a cardiac cause
  • diagnosed with panic disorder and or depression according to Diagnostic and statistical Manual (DSM) IV criteria
  • Living \< 50 km from the hospital
  • informed consent

Exclusion Criteria

  • other primary DSM IV diagnosis
  • known sensitivity to sertraline
  • using other anti-depressive agents
  • not speaking dutch language
  • living in a nursery home or having dementia
  • other severe, acute or progressive disease, kidney or liver-function disturbances, pregnancy or breastfeeding

Arms & Interventions

sertraline, panic education

treatment with sertraline after panic education

Intervention: sertraline

placebo after panic education

treatment with placebo after panic education

Intervention: placebo

Outcomes

Primary Outcomes

panic attacks

Time Frame: 24 weeks

reduction of panic attacks by more than or equal to 50%

17 items Hamilton depression (HAMD) rating scale score

Time Frame: 24 weeks

reduction of HAMD score of \>50%

Secondary Outcomes

  • Hospital Anxiety and Depression Scale (HADS)reduction score(24 weeks)
  • Clinical Global Impression (CGI) improvement(24 weeks)
  • EuroQol (EQ-5D)score(24 weeks)
  • Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) score(24 weeks)
  • health care costs(24 weeks)

Study Sites (1)

Loading locations...

Similar Trials